<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608618</url>
  </required_header>
  <id_info>
    <org_study_id>CP-M11-101</org_study_id>
    <nct_id>NCT03608618</nct_id>
  </id_info>
  <brief_title>Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma</brief_title>
  <official_title>A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaxCyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial and Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MaxCyte, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 dose escalation study to characterize the feasibility, safety and&#xD;
      tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly&#xD;
      doses for women with platinum resistant high grade serous adenocarcinoma of the ovary,&#xD;
      primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with&#xD;
      recurrence after prior chemotherapy. The study will also assess multiple cycles of treatment&#xD;
      and adding preconditioning with cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor shift in focus&#xD;
  </why_stopped>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">August 24, 2021</completion_date>
  <primary_completion_date type="Actual">February 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events as assessed by CTCAE v.5.0</measure>
    <time_frame>6 weeks</time_frame>
    <description>number and severity of adverse events according to NCI CTCAE v.5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>from first MCY-M11 dosing to first documented progression, assessed up to 24 months</time_frame>
    <description>tumor response scored by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)</measure>
    <time_frame>from first MCY-M11 dosing to first documented progression, assessed up tp 24 months</time_frame>
    <description>tumor response scored by irRECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Peritoneal Mesothelioma</condition>
  <condition>Fallopian Tube Adenocarcinoma</condition>
  <condition>Adenocarcinoma of the Ovary</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 and 2i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 and 3i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 and 4i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCY-M11</intervention_name>
    <description>Intraperitoneal administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2 and 2i</arm_group_label>
    <arm_group_label>Cohort 3 and 3i</arm_group_label>
    <arm_group_label>Cohort 4 and 4i</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous administration for preconditioning</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2 and 2i</arm_group_label>
    <arm_group_label>Cohort 3 and 3i</arm_group_label>
    <arm_group_label>Cohort 4 and 4i</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to undergo peripheral blood leukapheresis; have successful placement of an&#xD;
             intraperitoneal catheter&#xD;
&#xD;
          -  Be diagnosed with one of the following: metastatic or unresectable high grade serous&#xD;
             adenocarcinoma involving the ovary, primary peritoneum, or fallopian tube with&#xD;
             peritoneal involvement, not including mixed histologies, OR unresectable epithelioid&#xD;
             or biphasic peritoneal mesothelioma&#xD;
&#xD;
          -  Be at least 4 weeks from previous anti-cancer therapy&#xD;
&#xD;
          -  Have a life expectancy of greater than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, trying to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Diagnosis of HIV or chronic active Hepatitis B or C&#xD;
&#xD;
          -  Symptomatic or uncontrolled brain metastases requiring current treatment&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Lack of recovery of prior mild adverse events due to earlier therapies&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Another previous or current malignancy within the last 3 years, with exceptions&#xD;
&#xD;
          -  Concomitant chronic use of steroids or NSAIDs&#xD;
&#xD;
          -  Concomitant use of complementary or alternative medication or therapy&#xD;
&#xD;
          -  Autoimmune disease or inflammatory disease within previous 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Dansky Ullmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>MaxCyte, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute, National Institutes of Health</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University at St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platinum resistant</keyword>
  <keyword>high grade serous adenocarcinoma</keyword>
  <keyword>recurrence after chemotherapy</keyword>
  <keyword>intraperitoneal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

